ICMR Bioethics Unit, National Centre for Disease Informatics and Research, (Indian Council of Medical Research), Bengaluru, Karnataka, India.
Indian J Pharmacol. 2019 May-Jun;51(3):214-221. doi: 10.4103/0253-7613.262456.
Advancements in the field of biomedical and health research pose new ethical challenges warranting the need for constant updation in the existing ethics guidance. Realizing this, revision of "Ethical Guidelines for Biomedical Research on Human Participants (2006)" was initiated in the year 2015. The preparation of guidelines was a participatory process involving large number of stakeholders from various backgrounds in order to get a variety of perspectives. The initial draft went through an extensive process of consultation at both regional and national level, with experts and stakeholders from academia, govt. agencies, departments and ministries, public and private institutions, pharmaceutical industry, non-governmental organizations, patient organizations, regulators, international agencies as well as with public. The revised "National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017" were released on October 12, 2017, and address ethical concerns, in accordance to the sociocultural milieu of our country. New sections have been added on informed consent process, vulnerability, biological materials, biobanking and datasets, responsible conduct of research, sociobehavioral research, research in emergencies or disasters. The revised guidelines must be followed by all stakeholders who are engaged in biomedical and health research including sponsors, institutions, ethics committees, and researchers. It is expected that the implementation of these guidelines would help to protect the dignity, rights, safety and well-being of research participants and also to improve the quality of biomedical and health research.
生物医学和健康研究领域的进展带来了新的伦理挑战,这就需要不断更新现有的伦理指南。意识到这一点,我们于 2015 年启动了对“人体生物医学研究伦理指南(2006 年)”的修订工作。指南的编写是一个参与式的过程,涉及到来自不同背景的众多利益攸关方,以获取各种不同的观点。最初的草案经过了广泛的地区和国家层面的磋商过程,与学术界、政府机构、部门和部委、公共和私营机构、制药业、非政府组织、患者组织、监管机构、国际机构以及公众的专家和利益攸关方进行了磋商。修订后的“涉及人体的生物医学和健康研究国家伦理指南,2017 年”于 2017 年 10 月 12 日发布,根据我们国家的社会文化环境,解决了伦理问题。新增加了关于知情同意过程、脆弱性、生物材料、生物库和数据集、负责任的研究行为、社会行为研究、紧急情况或灾害研究的章节。所有从事生物医学和健康研究的利益攸关方,包括赞助商、机构、伦理委员会和研究人员,都必须遵守这些修订后的指南。预计这些指南的实施将有助于保护研究参与者的尊严、权利、安全和福祉,并提高生物医学和健康研究的质量。